UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer and infectious diseases.
Founded in Portland, OR in 2005 as a spinout of the Robert W. Franz Cancer Research Center within the Earle A. Chiles Research Institute, at Providence Portland Medical Center, UbiVac continues to build upon the groundbreaking research being developed in the region.
In 2011, UbiVac in cooperation with Oregon Health & Science University created UbiVac-CMV Inc., to license a disabled cytomegalovirus (CMV) vector technology for use as a vaccine. This technology is actively being developed in collaboration with our research partners.
Chicago, IL. June 2, 2017
UbiVac announced the results of their randomized phase II adjuvant clinical trial in patients with definitively-treated Stage III non-small cell lung cancer (NSCLC). Their data document the ability of UbiVac’s DRibble® cancer vaccine, DPV-001, to expand T cell clones and correlates with induction of immunity against a spectrum of non-small cell lung cancer antigens.
Portland, OR. May 12, 2017
UbiVac, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder, Bernard A. Fox, PhD, will address the International Symposium on Immunotherapy held 12-13 May at the Royal Society, London, England.